US00449L1026 - ADR
ACHILLES THERAPEUTICS PL-ADR
NASDAQ:ACHL (3/28/2024, 8:00:00 PM)
After market: 1.27 +0.02 (+1.6%)1.25
+0.06 (+5.04%)
Achilles Therapeutics Plc is a biopharmaceutical company engages in developing transformative precision T-cell therapies to treat multiple types of solid tumors. The firm develops transformative precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. The company is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. The company refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
ACHILLES THERAPEUTICS PL-ADR
245 Hammersmith Road, Gunnels Wood Road
London W6 8PW
P: 442081544600
CEO: Iraj Ali
Employees: 234
Website: https://www.achillestx.com/
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered...
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies...
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 –
Here you can normally see the latest stock twits on ACHL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: